Correction: Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings

null, null
December 2014
PLoS ONE;Dec2014, Vol. 9 Issue 12, p1
Academic Journal
No abstract available.


Related Articles

  • The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States. Shah, Maunank; Risher, Kathryn; Berry, Stephen A.; Dowdy, David W. // Clinical Infectious Diseases;1/15/2016, Vol. 62 Issue 2, p220 

    Background: Recent guidelines advocate early antiretroviral therapy (ART) to decrease human immunodeficiency virus (HIV) morbidity and prevent transmission, but suboptimal engagement in care may compromise impact. We sought to determine the economic and epidemiologic impact of incomplete...

  • The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa -- a primary data analysis. Cleary, Susan M.; McIntyre, Di; Boulle, Andrew M. // Cost Effectiveness & Resource Allocation;2006, Vol. 4, p20 

    Background: Given the size of the HIV epidemic in South Africa and other developing countries, scaling up antiretroviral treatment (ART) represents one of the key public health challenges of the next decade. Appropriate priority setting and budgeting can be assisted by economic data on the costs...

  • Ethical Challenges In Long-Term Funding For HIV/AIDS. Brock, Dan W.; Wikler, Daniel // Health Affairs;Nov/Dec2009, Vol. 28 Issue 6, p1666 

    The global response to the AIDS pandemic aims for universal access to treatment and for pursuing every possible avenue to prevention. Skeptics, doubting that the huge increases in current funding levels needed for universal treatment will ever happen, would scale back antiretroviral treatment in...

  • The Changing Natural History of HIV Disease: Before and After the Introduction of Generic Antiretroviral Therapy in Southern India. Kumarasamy, N.; Solomon, Suniti; Chaguturu, Sreekanth K.; Cecelia, Anitha J.; Vallabhaneni, Snigdha; Flanigan, Timothy P.; Mayer, Kenneth H. // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1525 

    The article focuses on the changing natural history of human immunodeficiency virus (HIV) infections before and after the introduction of generic antiretroviral therapy in India. The number of individuals seeking treatment for infection with HIV increased as the cost of highly active...

  • The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. Rosen, Sydney; Long, Lawrence; Sanne, Ian; Stevens, Wendy S.; Fox, Matthew P. // Journal of the International AIDS Society;2011, Vol. 14 Issue 1, p1 

    Background: Current guidelines for providing antiretroviral therapy (ART) in South Africa's public sector programme call for switching patients from first-line to second-line treatment upon virologic failure as indicated by two consecutive viral loads above 5000 copies/ml, but without laboratory...

  • Cotrimoxazole defeats HAART in Eastern Uganda.  // PharmacoEconomics & Outcomes News;1/9/2010, Issue 594, p7 

    The article discusses a study of the cost effectiveness of home-based provision of antiretroviral therapy in Uganda. A deterministic cost-effectiveness model was developed by researchers. Results revealed that highly active antiretroviral therapy (HAART) is less cost effective than many HIV...

  • Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to- Child Transmission of HIV. Galárraga, Omar; Wirtz, Veronika J.; Figueroa-Lara, Alejandro; Santa-Ana-Tellez, Yared; Coulibaly, Ibrahima; Viisainen, Kirsi; Medina-Lara, Antonieta; Korenromp, Eline L. // PharmacoEconomics;2011, Vol. 29 Issue 7, p579 

    As antiretroviral treatment (ART) for HIV/AIDS is scaled up globally, information on per-person costs is critical to improve efficiency in service delivery and to maximize coverage and health impact. The objective of this study was to review studies on unit costs for delivery of adult and...

  • Routine antiretroviral resistance testing of value in HIV infections.  // PharmacoEconomics & Outcomes News;4/10/2004, Issue 450, p9 

    Discusses research being done on the cost effectiveness of using genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Reference to a study by M. Corzillius and colleagues, published in the February 2004 issue of "Antiviral Therapy" journal; Construction...

  • Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States. Walensky, Rochelle P.; Sax, Paul E.; Nakamura, Yoriko M.; Weinstein, Milton C.; Pei, Pamela P.; Freedberg, Kenneth A.; Paltiel, A. David; Schackman, Bruce R. // Annals of Internal Medicine;1/15/2013, Vol. 158 Issue 2, p84 

    Background: U.S. HIV treatment guidelines recommend branded once-daily, 1-pill efavirenz-emtricitabine-tenofovir as first-line antiretroviral therapy (ART). With the anticipated approval of generic efavirenz in the United States, a once-daily, 3-pill alternative (generic efavirenz, generic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics